Alfa Invest

Turkey

Founded in

2022 (4 Years)

Founded

Last online: No recent activity

Claim company Visit website

TrustScore unavailableNot enough score to display the trend.

Be the first to rate and review this company.

OVERALL SCORE

Licenses

--/40

Reviews

--/60

0 reviews

Provided by TrustFinance

TrustScore unavailableNot enough score to display the trend.

Be the first to rate and review this company.

TrustFinance is not a licensed financial advisor and is not affiliated with any financial institutions in your region. We encourage you to do your own research before making any investment decisions.

Markets.com

(326 reviews)

United States

2008

(18 years)

Security Information :

FSCA

Security Information

Warning

This company is currently Unproved.

Please be cautious of the potential risks!

License

A Grade License

Issued by globally renowned regulators, these licenses ensure the highest trader protection through strict compliance, fund segregation, insurance, and regular audits. Dispute resolution and adherence to AML/CTF standards further enhance security.

B Grade License

Granted by respected regional regulators, these licenses offer robust safety measures such as fund segregation, financial reporting, and compensation schemes. Though slightly less strict than Tier 1, they provide dependable regional protection.

C Grade License

Issued by regulators in emerging markets, these licenses offer basic protections such as minimum capital requirements and AML policies. Oversight is less stringent, so traders should exercise caution and verify safety measures.

D Grade License

From jurisdictions with minimal oversight, these licenses often lack key protections like fund segregation and insurance. While attractive for operational flexibility, they pose higher risks to traders.

TrustFinance is not a licensed financial advisor and is not affiliated with any financial institutions in your region. We encourage you to do your own research before making any investment decisions.

Users who look Alfa Invest also look…

IUX

XM

FXGT

Deriv

Exness

IUX

XM

FXGT

Deriv

Exness

News

TrustFinance Intelligence Agency

Research date: 6월 28, 2026

S&P Global Ratings upgraded Alfa S.A.B. de C.V.'s credit rating from 'BBB-' to 'BBB' following the completion of its spin-off from Alpek S.A.B. de C.V., improving its business structure and leverage. The stable outlook reflects expectations of continued support from its subsidiary Sigma, which is now responsible for Alfa's financial health. Alfa's debt decreased significantly post-spin-off, and the ratings agency anticipates stable cash flow and prudent financial policies from Sigma for the next two years. Future ratings could be affected by Sigma's performance and Alfa's liquidity management.

S&P Global Ratings upgraded Alfa S.A.B. de C.V.'s credit rating from 'BBB-' to 'BBB' following the completion of its spin-off from Alpek S.A.B. de C.V., improving its business structure and leverage. The stable outlook reflects expectations of continued support from its subsidiary Sigma, which is now responsible for Alfa's financial health. Alfa's debt decreased significantly post-spin-off, and the ratings agency anticipates stable cash flow and prudent financial policies from Sigma for the next two years. Future ratings could be affected by Sigma's performance and Alfa's liquidity management.

The article explains the concept of alpha in investment, which measures the excess return of a portfolio compared to its expected return based on the capital asset pricing model (CAPM). It discusses how alpha helps investors evaluate the performance of portfolio managers by comparing realized returns with required returns adjusted for risk. A positive alpha indicates better-than-expected performance, while a negative alpha suggests underperformance. The article also emphasizes the importance of comparing funds within the same asset class and using appropriate benchmarks for accurate assessment.

The article explains the concept of alpha in investment, which measures the excess return of a portfolio compared to its expected return based on the capital asset pricing model (CAPM). It discusses how alpha helps investors evaluate the performance of portfolio managers by comparing realized returns with required returns adjusted for risk. A positive alpha indicates better-than-expected performance, while a negative alpha suggests underperformance. The article also emphasizes the importance of comparing funds within the same asset class and using appropriate benchmarks for accurate assessment.

Bicara Therapeutics Inc. announced three-year follow-up results from its Phase 1/1b study of ficerafusp alfa combined with pembrolizumab for treating HPV-negative head and neck squamous cell carcinoma (HNSCC). The study, presented at the ASCO26 medical conference, showed sustained deep responses in about 90 patients, marking a significant development in immuno-oncology. The company also launched the FORTIFI clinical trial targeting this patient group, reflecting its commitment to addressing unmet medical needs.

Bicara Therapeutics Inc. announced three-year follow-up results from its Phase 1/1b study of ficerafusp alfa combined with pembrolizumab for treating HPV-negative head and neck squamous cell carcinoma (HNSCC). The study, presented at the ASCO26 medical conference, showed sustained deep responses in about 90 patients, marking a significant development in immuno-oncology. The company also launched the FORTIFI clinical trial targeting this patient group, reflecting its commitment to addressing unmet medical needs.

Provided by TrustFinance AI Analysis

Reviews

Alfa Invest Reviews

Reviews

Total 0

AI Review analysis

Let’s TrustFinance AI Summarize all the reviews for you.

Provided by TrustFinance AI Analysis

Sort by

Filter

News

TrustFinance Intelligence Agency

Research date: 6월 28, 2026

S&P Global Ratings upgraded Alfa S.A.B. de C.V.'s credit rating from 'BBB-' to 'BBB' following the completion of its spin-off from Alpek S.A.B. de C.V., improving its business structure and leverage. The stable outlook reflects expectations of continued support from its subsidiary Sigma, which is now responsible for Alfa's financial health. Alfa's debt decreased significantly post-spin-off, and the ratings agency anticipates stable cash flow and prudent financial policies from Sigma for the next two years. Future ratings could be affected by Sigma's performance and Alfa's liquidity management.

The article explains the concept of alpha in investment, which measures the excess return of a portfolio compared to its expected return based on the capital asset pricing model (CAPM). It discusses how alpha helps investors evaluate the performance of portfolio managers by comparing realized returns with required returns adjusted for risk. A positive alpha indicates better-than-expected performance, while a negative alpha suggests underperformance. The article also emphasizes the importance of comparing funds within the same asset class and using appropriate benchmarks for accurate assessment.

Bicara Therapeutics Inc. announced three-year follow-up results from its Phase 1/1b study of ficerafusp alfa combined with pembrolizumab for treating HPV-negative head and neck squamous cell carcinoma (HNSCC). The study, presented at the ASCO26 medical conference, showed sustained deep responses in about 90 patients, marking a significant development in immuno-oncology. The company also launched the FORTIFI clinical trial targeting this patient group, reflecting its commitment to addressing unmet medical needs.

Provided by TrustFinance AI Analysis

Alfa Invest

Security Information

Company Information

Reviews

Alfa Invest

Security Information

Company Information

Users who look Alfa Invest also look…

IUX

XM

FXGT

Deriv

Exness

IUX

XM

FXGT

Deriv

Exness

News

TrustFinance Intelligence Agency

Reviews

Users who look Alfa Invest also look…

IUX

XM

FXGT

Deriv

Exness

IUX

XM

FXGT

Deriv

Exness

News

TrustFinance Intelligence Agency